Jeryl L. Hilleman net worth and biography

Jeryl Hilleman Biography and Net Worth

Director of NovoCure
Jeryl Hilleman became a director of Novocure in July 2018. Ms. Hilleman recently retired from Intersect ENT, a medical device company with commercial products for the treatment of chronic sinusitis, where she served as Chief Financial Officer from 2014 to 2019. Prior to joining Intersect ENT, she was Chief Financial Officer of Amyris Inc., a multi-national, renewable products company based in California and Brazil, from 2008 to 2012. Ms. Hilleman was a member of the board of directors and chair of the audit committee at Xenoport Inc., from 2004 to July 2018. She also served as Chief Financial Officer of Symyx Technologies, Ocera and Cytel. She is also a director of Minerva Neurosciences. Ms. Hilleman holds an A.B. from Brown University and an MBA from the Wharton Graduate School of Business. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.

What is Jeryl L. Hilleman's net worth?

The estimated net worth of Jeryl L. Hilleman is at least $185,759.14 as of June 10th, 2022. Ms. Hilleman owns 2,537 shares of NovoCure stock worth more than $185,759 as of September 26th. This net worth approximation does not reflect any other investments that Ms. Hilleman may own. Learn More about Jeryl L. Hilleman's net worth.

How do I contact Jeryl L. Hilleman?

The corporate mailing address for Ms. Hilleman and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected] Learn More on Jeryl L. Hilleman's contact information.

Has Jeryl L. Hilleman been buying or selling shares of NovoCure?

Jeryl L. Hilleman has not been actively trading shares of NovoCure during the last quarter. Most recently, Jeryl L. Hilleman sold 407 shares of the business's stock in a transaction on Friday, June 10th. The shares were sold at an average price of $69.61, for a transaction totalling $28,331.27. Following the completion of the sale, the director now directly owns 2,537 shares of the company's stock, valued at $176,600.57. Learn More on Jeryl L. Hilleman's trading history.

Who are NovoCure's active insiders?

NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Pritesh Shah (Insider), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.

Are insiders buying or selling shares of NovoCure?

During the last twelve months, NovoCure insiders bought shares 1 times. They purchased a total of 4,974 shares worth more than $509,536.56. During the last twelve months, insiders at the medical equipment provider sold shares 15 times. They sold a total of 37,658 shares worth more than $2,919,218.44. The most recent insider tranaction occured on September, 15th when insider Frank X Leonard sold 12,271 shares worth more than $1,086,228.92. Insiders at NovoCure own 6.2 % of the company. Learn More about insider trades at NovoCure.

Information on this page was last updated on 9/15/2022.

Jeryl L. Hilleman Insider Trading History at NovoCure

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/10/2022Sell407$69.61$28,331.272,537View SEC Filing Icon  
12/18/2020Sell2,500$166.40$416,000.003,400View SEC Filing Icon  
See Full Table

Jeryl L. Hilleman Buying and Selling Activity at NovoCure

This chart shows Jeryl L Hilleman's buying and selling at NovoCure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NovoCure Company Overview

NovoCure logo
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Read More

Today's Range

Now: $73.22
Low: $71.35
High: $74.43

50 Day Range

MA: $79.13
Low: $67.99
High: $89.57

2 Week Range

Now: $73.22
Low: $56.39
High: $130.74


533,300 shs

Average Volume

625,677 shs

Market Capitalization

$7.67 billion

P/E Ratio


Dividend Yield